2025年12月31日，迈瑞医疗披露接待调研公告，公司于10月31日至12月31日接待淡水泉（北京）投资管 理有限公司、MY．Alpha Management HK Advisors Limited、Neuberger Berman、Nine Masts Capital Limited、Nordea Investment Management、OLP Capital Management Ltd．等205家机构调研。 调研情况显示，迈瑞医疗表示国内市场受多重因素影响暂时承压，但IVD市场存在进口替代历史性机 遇，计划三年内化学发光、生化、凝血领域市占率翻倍，数智化解决方案可提升赢单率并避免低价竞 争；长期看，微创外科、微创介入等新兴业务市场容量大于IVD，随手术量和渗透率增长潜力显著，预 计2026年国内业务实现正增长，2027年后增速有望提速并维持盈利稳定。 针对超声市场竞争，迈瑞医疗指出该行业具有高专业壁垒和细分特点，公司凭借近30年积累，已建立全 面领先的产品线与专科解决方案、深刻的临床洞察与智能化融合生态、全球化平台与品牌效应三大核心 优势，将持续技术创新巩固领先地位；启元系大模型已在浙大一院、仁济医 ...

当天，美莱医疗还举行了胸部内窥镜&超声刀学术带教会。熊猛开展实操演示，实时展示手术流程与关键技术细节。随后，他发表《筋膜 下隆乳—假体隆乳新赛道》主题演讲，结合30余年临床经验，深度解析该联合技术的优势，二者协同应用于筋膜下隆乳，更有利于实现术后 形态自然。 据悉，四川美莱于2014年首次引进内窥镜，2015年成立数字化内窥镜隆乳技术临床应用基地，2022年2月引入首台超声刀。未来，美莱医 疗将持续以学科建设为核心，持续为广大顾客提供更优质的医美服务。 12月9日，美莱医疗学术管理部内窥镜美容专业委员会在四川美莱成立。 此举将进一步整合美莱医疗优势资源，推动技术规范与创新，推动胸部整形领域内窥镜临床应用，还为青年医师作出示范，助力胸部整 形人才建设。美莱集团总院长艾玉峰，四川美莱整形外科总院长、美莱胸部学科带头人熊猛，四川美莱整形外科技术院长、美莱胸部学科骨 干医师詹磊及青年医生出席仪式。 据介绍，该专委会将以技术研讨、人才培养、标准制定为核心，助力行业内窥镜美容技术的体系化发展。这不仅是美莱学科建设的里程 碑，更为顾客提供更安心、更有效的医美体验。 ...

迈瑞医疗认为，展望国内市场，短期的行业扰动无法避免，公司已经及时地调整了应对策略。首先，公 司认为国内业务最艰难的时刻已经过去；第二，当前的市场环境给了迈瑞加速国产扩容和加快行业集中 度提升这一历史性机遇，因此公司将国内业务考核的重心放在了市场份额上，尤其是重点考核IVD业务 大规模突破大样本量客户，国内各项业务的市占率均在稳步提升；第三，公司持续倾斜资源投入在流水 型业务和国际市场。微创外科中的高值耗材超声刀、腔镜吻合器有望从今年开始在国内放量，这部分业 务的市场容量远比传统生命信息与支持业务要大，同时未来的成长性也要比传统业务更强，并且得益于 海外高端客户的加速突破，国际业务后续的增长也将提速。 目前，迈瑞医疗正全力冲击全球医疗器械排名前20的目标。公司的监护仪、麻醉机、呼吸机、除颤仪、 血球、超声产品在全球的市场占有率维持前三的地位。随着"国际化""数智化""流水化"战略的发展，公 司有望向更高的市场地位发起冲击。 实际上，增持之初，李西廷就已公布了后续计划——未来6个月内，以自有资金继续在深交所以集中竞 价交易方式增持公司股份，拟增持计划总金额为2亿元，且增持不设价格区间，锁定期为增持计划实施 完成后 ...

公司核心创始人连续增持的背后，包含了对于迈瑞医疗未来发展的信心。从经营数据来看，尽管 2025年前三季度迈瑞医疗业绩因高基数等因素承压，但第三季度单季营收已实现同比增长1.53%，如期 迎来拐点。公司近期在互动易平台表示，预计明年国内业务有望恢复正增长，2026年利润增速或将转 正。在这一背景下，核心创始人以自有资金增持，向市场释放了对未来业绩回暖与长期增长的坚定信 心。 迈瑞医疗认为，展望国内市场，短期的行业扰动无法避免，公司已经及时地调整了应对策略。首 先，公司认为国内业务最艰难的时刻已经过去；第二，当前的市场环境给了迈瑞加速国产扩容和加快行 业集中度提升这一历史性机遇，因此公司将国内业务考核的重心放在了市场份额上，尤其是重点考核 IVD业务大规模突破大样本量客户，国内各项业务的市占率均在稳步提升；第三，公司持续倾斜资源投 入在流水型业务和国际市场。微创外科中的高值耗材超声刀、腔镜吻合器有望从今年开始在国内放量， 这部分业务的市场容量远比传统生命信息与支持业务要大，同时未来的成长性也要比传统业务更强，并 且得益于海外高端客户的加速突破，国际业务后续的增长也将提速。 目前，迈瑞医疗正全力冲击全球医疗器械排名 ...

Investment Rating - The report assigns an "Outperform" rating to the company for the first time, with a reasonable valuation range of 28.85 to 30.40 CNY, indicating a potential premium of 22.9% to 29.5% over the current stock price of 23.48 CNY [6][3]. Core Insights - The company is a leading domestic manufacturer of helium mass spectrometers, focusing on industrial detection and online monitoring instruments, while also expanding into laboratory analysis and medical instruments to create a second growth curve [1][2]. - The industrial detection and online monitoring segments are expected to solidify the company's revenue base, with projected revenues of 4.55 billion CNY and 1.98 billion CNY respectively for 2024 [1]. - The laboratory analysis and medical instruments are emerging as new growth engines, with expected revenues of 0.47 billion CNY for laboratory instruments and ongoing development in medical devices [2]. - The company is poised for growth due to recovering product demand, expansion into downstream applications, and strong government support for domestic alternatives in laboratory and medical instruments [3]. Summary by Sections Company Overview - Founded in 2003, the company has evolved from a regional technology firm to a national-level specialized "little giant" and is listed on the Sci-Tech Innovation Board [13]. - The company operates across four main business segments: industrial detection instruments, online monitoring instruments, laboratory analysis instruments, and medical instruments, forming a synergistic growth model [1]. Financial Performance - The company has experienced significant revenue growth, with a compound annual growth rate (CAGR) of 11.99% from 2020 to 2024, despite facing profit pressures due to high R&D investments [23]. - In 2025, the company is expected to see a substantial improvement in performance, with projected revenues of 8.99 billion CNY and net profits of 660 million CNY, reflecting a year-on-year growth of 358.5% [5][3]. Business Segments - The industrial detection segment is the primary revenue contributor, projected to generate 4.55 billion CNY in 2024, while online monitoring instruments are expected to account for 1.98 billion CNY [1][45]. - The laboratory analysis instruments and medical devices are still in the early stages of revenue contribution, with laboratory instruments expected to generate 0.47 billion CNY in 2024 [2][45]. Growth Drivers - The demand for industrial detection instruments is anticipated to benefit from the expansion of major battery manufacturers and government policies aimed at environmental monitoring [3]. - The company has implemented a stock incentive plan to align employee interests with company performance, which is expected to further drive growth [20][21].

Core Viewpoint - 九州通's total brand promotion business (CSO) achieved a sales revenue of 14.728 billion yuan in the first three quarters of 2025, demonstrating steady growth [1] Group 1: Pharmaceutical CSO Business - The pharmaceutical CSO business generated a sales revenue of 8.740 billion yuan, reflecting a year-on-year growth of 15.26%, primarily driven by the strong performance of core products such as 可威 and 弥可保 [1] - The company has introduced 81 new product specifications during the period, including 9 high-value products, and has secured the distribution rights for 8 specifications of 卡泊三醇 in retail channels through collaboration with 利奥中国 [1] - 九州通's platforms, including 全擎健康, currently represent 783 product specifications, with 32 products achieving annual sales exceeding 100 million yuan, covering chronic diseases and anti-infection areas [1] Group 2: Medical Device CSO Business - The medical device CSO business recorded a sales revenue of 5.987 billion yuan, facing challenges due to the impact of medical consumables procurement policies on certain products like ultrasound knives and staplers [1] - The company represents 1,386 product specifications from 11 major manufacturers, including brands like 强生, 罗氏, and 雅培, across 15 product lines [1] - New product introductions, such as 登士柏 (dental) and 加奇, have shown rapid growth, with sales revenue exceeding 180 million yuan in the first three quarters [1]

Group 1 - 九州通 has established a new medical device company with a registered capital of 10 million, expanding its footprint in the medical device sector [1] - In September alone, two new medical device companies under 九州通 were founded, bringing the total to at least 18 new companies established this year across various provinces [1] - 九州通's third-quarter revenue reached 38.22 billion, a year-on-year increase of 5.41%, with net profit at 530 million, up 8.46% [1] Group 2 - The medical device business of 九州通 has shown strong growth, achieving sales revenue of 28.963 billion, a year-on-year increase of 17.20% [1] - The "国补" policy has significantly boosted online medical device sales, contributing to a total revenue of 5.37 billion from online operations [2] - 九州通's agency brand promotion business generated sales revenue of 5.987 billion in the first three quarters, despite some impact from centralized procurement [2] Group 3 - The "以旧换新" policy for medical devices has driven 九州通's equipment business growth, resulting in sales revenue of 5 billion, a year-on-year increase [3] - 九州通 has developed a digital supply chain system and smart cabinets for medical supplies, enhancing the tracking of personnel and goods [3] - The company is adapting to market changes and challenges posed by traditional sales models, emphasizing the need for rapid adaptation in the pharmaceutical distribution sector [3]

Core Viewpoint - The company has successfully increased its market share in the in vitro diagnostics (IVD) sector while maintaining stable gross margins, thanks to its core technology and strategic responses to national procurement policies [1] Market Share and Procurement - Since the second half of 2021, the company has actively participated in multiple centralized procurement projects, leveraging its multi-product line advantage in the IVD field to expand market share [1] - The company's market ranking in the chemiluminescence business has improved to third place domestically, while its biochemical business has surpassed a 15% market share for the first time [1] - The company has successfully won multiple bids for high-value consumables in 2024, including ultrasound knives and laparoscopic anastomosis devices, breaking into top-tier hospitals [1] Profitability and Cost Management - The company has managed to maintain its gross margin despite increased market share, primarily due to its mastery of core technologies [1] - The company aims to reduce the cost of chemiluminescence reagents by at least 50% over three years through increased self-manufacturing of core raw materials [1] - The introduction of new high-end ultrasound devices has allowed the company to double the price compared to previous models due to significant improvements in image performance [1] Innovation and Marketing - The company's technological innovations are increasingly competitive with imported brands, with some products leading in technology, which accelerates the acquisition of high-end clients [1] - The strategy to increase the revenue share of flow-type businesses, such as IVD reagents and high-value consumables, is expected to positively impact future profitability [1] Employee Engagement and Management - The company conducts regular employee surveys to assess management effectiveness and drive improvements, with a participation rate of 92.64% in the latest survey [1] - Survey results indicate that 84.78% of employees are engaged, and 80.23% express overall recognition of the company's management, culture, and development [1] - Approximately 89.16% of employees are confident in the company's future development [1]

Core Viewpoint - Mindray Medical's H1 2025 net profit attributable to shareholders is 5.069 billion yuan, a decrease of 32.96%, with Q2 net profit at 2.440 billion yuan, down 44.55% [1] Group 1: Market Performance - The international market shows steady growth, while the domestic market is under short-term pressure, awaiting a turning point [1] - Tender activities have seen a recovery in the first half of the year, with expectations for significant improvement in the domestic market in Q3 [1] Group 2: Product Development - In H1 2025, the company plans to launch 8 new chemiluminescence reagent products, increasing the total number of NMPA-approved products to 88 [1] - The MT8000 production line has received 185 new orders and nearly 100 new installations, with an annual installation target of 200 sets [1] Group 3: Business Growth - This year marks a significant growth year for minimally invasive surgical core products such as ultrasonic knives and endoscopic staplers, providing strong momentum for long-term growth in this business segment [1] Group 4: Valuation - Based on the DCF model, the overall valuation of the company is estimated at 353.9 billion yuan, with a target price of approximately 292 yuan, corresponding to a PE ratio of 27X for 2026 [1]

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 292 CNY, reflecting an expected performance that exceeds the benchmark index by 10%-20% over the next six months [8][24]. Core Insights - The company reported a revenue of 16.743 billion CNY for the first half of 2025, a decrease of 18.45% year-on-year, and a net profit attributable to shareholders of 5.069 billion CNY, down 32.96% [2]. - The international market shows steady growth, with a 5.39% increase in revenue, while the domestic market is expected to improve in Q3 2025 due to the revival of bidding activities [8]. - The in-vitro diagnostics (IVD) business is accelerating its internationalization, achieving double-digit growth in international markets, despite a 16.11% decline in domestic revenue [8]. - The medical imaging segment benefits from the launch of high-end ultrasound systems, maintaining a strong market share despite overall procurement pressures in the domestic market [8]. - The life information and support business faces domestic challenges but is expected to gain momentum from the introduction of high-value consumables [8]. Financial Summary - For 2025, the company is projected to achieve a net profit of 11.79 billion CNY, reflecting a year-on-year growth of 1.0%, with further growth expected in subsequent years [4]. - The company's earnings per share (EPS) is forecasted to be 9.72 CNY in 2025, with a price-to-earnings (P/E) ratio of 25 [4]. - The total revenue is expected to grow from 36.726 billion CNY in 2024 to 49.086 billion CNY by 2027, with a compound annual growth rate (CAGR) of 14.4% [4]. Market Performance - The company’s stock price has shown fluctuations, with a 12-month high of 324.50 CNY and a low of 211.59 CNY, indicating volatility in market performance [5].